促肝细胞生长素对慢性肝炎、慢性重症肝炎患者 血清IL-6和IL-8的影响

摘要

Objective To study serum interleukin 6 and 8(IL-6,IL-8) inchronic and chronic severe hepatitis patients to observe the effects of hepatocyte growth promoting factor (pHGF) therapy.Methods Using sandwich ELISA method,we tested serum IL-6 and IL-8 in 64 chronic and chronic severe hepatitis patients to observe the effects of pHGF therapy.Results The results showed that IL-6 and IL-8 levels abnormally increased in the patients we observed (P＜0.05～0.01). In chronic severe and chronic hepatitis patients it was significantly higher than the control group (P＜0.01). After 4 weeks pHGF therapy,in the chronic hepatitis patients group IL-6 levels was obviously decreased (P＜0.05). Eight weeks later,IL-6 and IL-8 levels were all reduced.For the chronic severe hepatitis patients 4 weeks of pHGF treatment could reduce serum IL-6 and IL-8 levels (P＜0.05).After 8 weeks treatment these factors were all decreased(P＜0.01).Meanwhile,IL-6 decreasing was related with ALT level.After 6 months in the efficacious cases HBeAg and HBV DNA conversion rate were 13/30,15/32 respectively and all the two factor levels were almost return to normal. In the patients group that failed to respond to medical treatment,their IL-6 and IL-8 were significantly higher than that of the group by pHGF treatment.Conclusion All these findings implied that IL-6 and IL-8 serum levels were related with the phases of chronic hepatitis and it reflected the extent of hepatocyte inflammation.So it can be used as an index to value the therapeutic effectiveness and to judge the patient's prognosis.Moreover, pHGF therapy can cure immunopathology dysfunction,improve liver's function and has the affects of anti-virus.%目的 研究观察慢性肝炎、慢性重症肝炎患者血清IL-6和IL-8水平在促肝细胞生长素(pHGF)治疗前后的变化。方法 采用酶联免疫吸附试验(ELISA)检测64例慢性肝炎和慢性重症肝炎患者pHGF治疗前及治疗后4周、8周血清IL-6和IL-8水平。结果 慢性肝炎及慢性重症肝炎患者血清IL-6、IL-8水平较正常对照组明显升高(P＜0.05～0.001)，且慢性重症肝炎＞慢性肝炎(中度)＞慢性肝炎(轻度)。pHGF治疗组的慢性肝炎和慢性重症肝炎患者在治疗8周后，其血清IL-6和IL-8水平明显下降(P＜0.05)，ALT与IL-6呈明显正相关；pHGF疗程结束后半年，其HBeAg、HBV-DNA转阴率为43.3%、46.9%，转阴组IL-6、IL-8水平接近正常，而阳性组则明显高于转阴组(P＜0.05)。结论 提示慢性肝炎和慢性重症肝炎患者血清IL-6和IL-8水平与慢性肝病肝脏损伤程度密切相关，是判定患者预后和疗效的重要指标。